Skip to main content
Intensive Care Medicine Experimental
Fig. 5 | Intensive Care Medicine Experimental

Fig. 5

From: Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats

Fig. 5

Adrecizumab decreases ROS production. Adrecizumab decreased ROS production in the septic myocardium within 3 h. Dihydroethidium (DHE; Sigma-Aldrich) staining was used to evaluate the in situ levels of superoxide anion in the myocardium. Data are expressed as a percentage of region of interest (percent of ROI). Kruskal-Wallis test followed by Dunn’s multiple comparison test was used. *p < 0.05 and ***p < 0.001

Back to article page